Overview

Iloprost in Acute Respiratory Distress Syndrome

Status:
Recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

The patients will be randomized into one of two groups. Both groups will receive standard care as is state of the art. The intervention group will receive Iloprost nebulized as inhalative therapy.

Phase:

Phase 3

Details

Lead Sponsor:

University Hospital Tuebingen

Treatments:

Iloprost